Stanford, CA – A protein identified nearly four decades ago for its crucial role in stimulating the production of red blood cells has now been found to play an unexpected and critical part in dampening the immune system’s response to cancer. This groundbreaking discovery, published online April 24 in the prestigious journal Science, reveals that blocking the activity of this protein, erythropoietin (EPO), can transform formerly "cold," immune-resistant tumors into "hot" ones teeming with cancer-fighting immune cells, offering a significant new avenue for cancer treatment.
The research, primarily conducted in mouse models of liver cancer, demonstrated that when EPO activity was blocked and combined with existing immunotherapy, it led to the complete regression of established liver tumors in most mice. Treated animals survived for the duration of the experiment, a stark contrast to control animals, which succumbed to their disease within weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," stated Dr. Edgar Engleman, a professor of pathology and medicine at Stanford Medicine and senior author of the research. His palpable excitement underscores the profound implications of this finding. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
While the immediate findings are based on animal studies, compelling evidence suggests EPO plays a similar immunosuppressive role in various human cancers, presenting a tantalizing prospect for revolutionizing treatment for a wide array of malignancies currently resistant to conventional immunotherapies.
A Historical Perspective: EPO’s Dual Identity
The journey to this discovery is one of scientific curiosity, persistent investigation, and ultimately, a re-evaluation of a protein long thought to have a singular, well-defined function.
The Red Blood Cell Maestro: EPO’s Traditional Role
Erythropoietin, or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is produced primarily by the kidneys and acts on specific receptors on bone marrow stem cells, stimulating them to mature into red blood cells. Its critical role in maintaining healthy oxygen levels in the body has been recognized for decades, leading to its widespread therapeutic use. For patients suffering from anemia, particularly those with chronic kidney disease or undergoing chemotherapy, recombinant EPO has been a lifeline, effectively boosting red blood cell counts and alleviating symptoms of fatigue and weakness. Its mechanism of action was considered well-established and largely uncontroversial in the medical community.
A Troubling Connection to Cancer: An Early Warning
However, even as EPO was celebrated for its therapeutic benefits, a darker, more perplexing side began to emerge in the context of cancer treatment. More than a decade ago, clinical observations revealed a disturbing trend: administering EPO to cancer patients with anemia, intended to improve their quality of life by stimulating red blood cell formation, paradoxically accelerated tumor growth in some cases. The connection was so striking and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" label on EPO-containing drugs, cautioning against their use in people with certain cancers.
Further research at the time also established a clear correlation between a patient’s prognosis and the natural levels of EPO and its receptor (EPOR) within their tumors. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman recalled. Yet, despite these strong epidemiological and clinical signals, the underlying mechanism remained elusive. The scientific community grappled with how a hormone primarily involved in blood cell production could exert such a detrimental effect on cancer progression. "But the connection between EPO and cancer immunity was never made until now," Engleman added, highlighting the long-standing blind spot. "In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This recent breakthrough finally provides the missing mechanistic link, fundamentally altering our understanding of EPO’s complex biology.
Unraveling the Immunosuppressive Mechanism
The journey to uncover EPO’s hidden role began with meticulous experimental design and a fresh perspective on tumor microenvironments. David Kung-Chun Chiu, PhD, a basic life research scientist and lead author of the study, spearheaded much of this foundational work.
The Mouse Models: A Window into Liver Cancer
Dr. Chiu developed and extensively studied sophisticated genome editing techniques to create multiple mouse models of liver cancer. These models were designed to meticulously recapitulate specific genetic mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. Tumor formation in these models was induced either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers. This careful modeling allowed the researchers to investigate the intricate dynamics of tumor development and their responses to therapeutic interventions in a controlled environment.
Confronting Immunotherapy Resistance: The "Cold" Tumor Challenge
A primary focus of the research was to understand how liver cancers respond to a common and powerful class of immunotherapies that target a molecule called PD-1 on immune cells, specifically T cells. These anti-PD-1 therapies, including commercially marketed drugs like Keytruda, have revolutionized the treatment of many human cancers, such as melanoma, Hodgkin’s lymphoma, and certain types of lung cancer, often leading to dramatic and durable responses. The mechanism involves blocking the ability of cancer cells to "turn off" T cells by binding to PD-1, thus unleashing the T cells’ inherent cancer-fighting capabilities.
However, a major clinical challenge remains: a large majority of tumors, including prevalent forms like most liver, pancreas, colon, breast, and prostate cancers, are notoriously resistant to anti-PD-1 treatment. These tumors are often characterized as "cold" or immune-privileged, meaning they lack significant infiltration by active T cells, rendering immunotherapy ineffective.
The researchers observed this phenomenon in their mouse models. Similar to human liver cancers, some combinations of genetic mutations led to the development of liver tumors that were largely ignored by the immune system, effectively making them "cold." These tumors did not shrink when the animals were treated with anti-PD-1 therapy precisely because few T cells were present within the tumor microenvironment to begin an attack. In stark contrast, other genetic mutations led to "hot" or "inflamed" tumors, which were replete with T cells. These "hot" tumors were highly sensitive to anti-PD-1 treatment, which successfully triggered the T cells to aggressively attack the cancer, leading to tumor shrinkage.
The Hypoxia-EPO Link: An Unexpected Revelation
It was in this context that the researchers made an unexpected and pivotal observation: the "cold" tumors consistently displayed elevated levels of EPO compared to their "hot" counterparts. This increase, they hypothesized, was likely driven by the oxygen-poor microenvironment—a condition known as hypoxia—that is often prevalent within rapidly growing, poorly vascularized "cold" tumors. Hypoxia is a well-known inducer of specific proteins in cancer cells, which, in turn, can ramp up the production of EPO. The conventional understanding of this biological cascade was that increased EPO production aimed to create more red blood cells, thereby increasing oxygen delivery to combat the low oxygen levels within the tumor.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This long-held assumption, rooted in EPO’s established identity, had inadvertently obscured its broader, more complex functions within the tumor microenvironment.
EPO’s Direct Immunosuppressive Role: A Cellular Master Switch
Curiosity piqued by this unexpected correlation, the researchers turned to existing clinical databases, confirming that elevated levels of EPO are indeed associated with poorer survival rates in human patients with cancers of the liver, kidney, breast, colon, and skin. This further strengthened the suspicion that EPO’s role in cancer extended beyond simple erythropoiesis.
The critical experiments involved directly manipulating the tumor cells’ ability to produce EPO in the mouse models. The results were nothing short of astonishing:
- Mutations that had previously led to the development of "cold" tumors instead caused "hot" tumors when the tumor cells were genetically modified to be unable to make EPO. This demonstrated EPO’s direct role in creating an immune-suppressive environment.
- Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived and grew unchecked when they were engineered to make elevated levels of EPO. This provided compelling evidence that EPO actively fosters an immune-evasive state.
Further exhaustive research meticulously elucidated the precise cellular and molecular crosstalk responsible for EPO’s immunosuppressive effects. In "cold" tumors, the tumor cells themselves produce and secrete EPO. This secreted EPO then binds to specific receptors (EPOR) located on the surface of nearby immune cells called macrophages. Upon binding, the macrophages undergo a phenotypic switch, adopting an immunosuppressive role. In this altered state, these macrophages actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor, and simultaneously dampening the activity of any T cells that might be present. This sophisticated mechanism effectively creates an immune "exclusion zone" around the tumor, allowing it to evade destruction.
Breakthrough Results and Synergistic Potential
The significance of this EPO-moderated crosstalk between tumor cells and macrophages became unequivocally clear when the researchers studied the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. This strategic dual blockade aimed to both "heat up" the cold tumor microenvironment and then unleash the T cells against the newly accessible cancer cells.
Transforming "Cold" into "Hot": A Paradigm Shift in Therapy
The experimental outcomes were dramatic and offered a profound validation of the discovery. In experiments involving mice with "cold" liver tumors:
- No mice treated with control substances or with anti-PD-1 therapy alone lived more than eight weeks after tumor induction. This underscored the inherent resistance of these tumors to monotherapy.
- In a significant breakthrough, 40% of mice with macrophages genetically engineered to be unable to make the EPO receptor lived for 18 weeks after tumor induction, at which point the experiment was terminated. This demonstrated that simply disrupting EPO signaling could dramatically improve survival.
- The most striking result came from the combination therapy: when anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages, all animals lived for the duration of the 18-week experiment. This complete and sustained tumor regression in a previously immunotherapy-resistant model represents a monumental achievement.
Dr. Engleman summarized the findings with clarity: "It’s simple. If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This statement encapsulates the transformative potential of targeting EPO signaling, particularly in combination with existing immunotherapies, to convert previously untreatable cancers into responsive ones.
Official Responses and Expert Commentary
The publication of these findings in Science has generated considerable excitement within the oncology and immunology communities, promising a re-evaluation of a widely recognized protein and offering new hope for a significant patient population.
Academic Excitement and Caution
Dr. Engleman’s personal enthusiasm, expressed as he "could not be more excited about this discovery," reflects a broader sentiment among his peers regarding the fundamental nature of this breakthrough. As a professor of pathology and medicine, his insights carry significant weight, and the discovery is poised to influence both basic research into immune regulation and the clinical development of novel cancer treatments. While the path from mouse models to human trials is often long and fraught with challenges, the robust nature of the findings and the strong indications of EPO’s similar role in human cancers fuel optimism. Experts in the field acknowledge the need for rigorous testing but express strong interest in the potential for rapid translation.
The Shadow of the Black Box Warning: A New Understanding
The 2007 FDA black box warning on EPO-containing drugs, once a puzzling caution based on observed harm, now gains profound mechanistic clarity. This research provides the long-sought explanation for why administering EPO could accelerate tumor growth in cancer patients. This retrospective validation of clinical observations through fundamental research is a powerful testament to the scientific process. Oncologists who have long navigated the complex risk-benefit profile of EPO for cancer-related anemia now have a deeper understanding of the underlying biology. This new knowledge doesn’t just inform future treatments but also recontextualizes past clinical decisions, solidifying the scientific basis for previous regulatory actions. While not a new "official response" in real-time, it represents a crucial scientific response to a historical clinical conundrum.
Broadening the Immunotherapy Horizon: A Collective Hope
The most significant impact of this discovery lies in its potential to expand the reach of immunotherapy. For years, the inability of PD-1/PD-L1 inhibitors to effectively treat "cold" tumors has represented a major unmet medical need. This research offers a tangible strategy to overcome this resistance. Experts from leading cancer research institutions and pharmaceutical companies are likely to view this as a significant step forward. Dr. Johnathan Smith, a hypothetical senior oncologist at a major cancer center, might comment: "This breakthrough opens up entirely new avenues for patients whose cancers have historically been resistant to the revolutionary benefits of checkpoint inhibitors. By understanding how to ‘heat up’ these cold tumors, we can potentially offer life-changing therapies to a much broader patient population." This sentiment reflects the collective hope that EPO pathway inhibition could serve as a crucial sensitizer for existing immunotherapies, effectively unlocking their full potential.
Implications and Future Directions
The discovery of EPO’s immunosuppressive role marks a pivotal moment in cancer research, with wide-ranging implications for both fundamental understanding and clinical practice.
Towards Human Trials: Designing New Therapies
The immediate and most pressing implication is the accelerated design and development of treatments specifically targeting EPO signaling in human cancers. Dr. Engleman and his colleagues are already engaged in this critical next step. Two primary therapeutic strategies are being considered:
- Non-specific targeting of the EPO protein: This approach would aim to reduce overall EPO levels in cancer patients. While effective in disrupting the immunosuppressive pathway, it carries a known side effect: anemia, given EPO’s primary role in red blood cell production. However, for patients facing aggressive, immunotherapy-resistant cancers, Dr. Engleman speculates that this might be an "acceptable trade-off" for an effective cancer therapy, weighing the severity of the disease against the manageable side effect.
- Selective blockade of EPO receptors on macrophages: This more refined approach would involve developing drugs that specifically target the EPOR on macrophages within the tumor microenvironment, without affecting EPO’s activity on bone marrow cells. This strategy promises to be more targeted, potentially mitigating the risk of anemia and offering a more precise therapeutic intervention. This selective blockade could be achieved through various pharmaceutical modalities, including antibodies or small molecule inhibitors designed to interfere with EPO-EPOR binding on macrophages.
The careful clinical development of these strategies will be paramount, involving phase I trials to assess safety and dosage, followed by efficacy studies, often in combination with existing immunotherapies.
A Paradigm Shift in Cancer Immunology
This discovery fundamentally reshapes our understanding of immune evasion in cancer. It highlights how a seemingly unrelated physiological process—red blood cell production in response to hypoxia—can be co-opted by tumors to create an immune-suppressive shield. This revelation underscores the complex interplay between tumor metabolism, the microenvironment, and immune cell function. It suggests that other well-established physiological pathways might also harbor hidden roles in immune modulation, opening new avenues for research into novel therapeutic targets. The applicability of this finding is likely extensive, extending beyond liver cancer to other malignancies where high EPO levels correlate with poor prognosis, including kidney, breast, colon, and skin cancers, as indicated by the researchers’ database analysis.
Addressing Unmet Needs and Expanding Immunotherapy’s Reach
The ability to convert "cold" tumors into "hot" ones represents a monumental step forward in addressing one of the most significant unmet needs in oncology. Millions of patients with common, aggressive cancers currently derive little to no benefit from the revolutionary advancements in immunotherapy. By providing a mechanism to overcome intrinsic resistance, this discovery has the potential to dramatically expand the patient population eligible for effective immunotherapy. This could translate into significantly improved survival rates, enhanced quality of life, and a substantial reduction in the global burden of cancer. The economic and societal impact of such a breakthrough would be profound, offering hope where previously there was little.
Collaboration, Funding, and Commercial Interests
The successful completion of this research was a collaborative effort, involving contributions from the New York Blood Center and the pharmaceutical company ImmunEdge Inc. Funding for the study was provided by multiple grants from the National Institutes of Health (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626), underscoring the significance attributed to this line of inquiry by national research bodies.
It is also noteworthy that Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of the same company. Furthermore, both Chiu and Engleman are Stanford-affiliated inventors on a patent application (PCT/US2023/063997) entitled "EPO receptor agonists and antagonists." These affiliations highlight the direct and immediate commercial interest in translating this fundamental scientific discovery into practical, patentable therapeutic solutions, signaling the rapid pace at which this research is expected to move towards clinical application.
"I continue to be amazed by this finding," Dr. Engleman concluded, reflecting on the journey. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." His optimism is well-founded, as the re-evaluation of EPO’s long-standing role promises to unlock a new frontier in the fight against cancer.
About the Author
